Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia

Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. We aimed to develop an in vivo model of RUNX1-mutated, CN-AML in which the nature of residual disease in this molecular disease subset c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivagnanalingam, Umayal, Balys, Marlene, Eberhardt, Allison, Wang, Nancy, Myers, Jason R., Ashton, John M., Becker, Michael W., Calvi, Laura M., Mendler, Jason H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503761/
https://www.ncbi.nlm.nih.gov/pubmed/26177509
http://dx.doi.org/10.1371/journal.pone.0132375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503761/
https://www.ncbi.nlm.nih.gov/pubmed/26177509
http://dx.doi.org/10.1371/journal.pone.0132375

Ejemplares similares